Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 11/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 10/20 | 1.00 |
| ▸ | BCL2 | P10415 | 9/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 4/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | LDHB | P07195 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apogossypol SCHEMBL29467534 | 1.00 | BCL2L1 (1.00) | BCL2L1MCL1BCL2BCL2L2ALB | |
| Apogossypol SCHEMBL2513478 | 1.00 | BCL2L1 (1.00) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL12200184 | 0.96 | BCL2L1 (0.93) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14958609 | 0.93 | MCL1 (0.87) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL30143373 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14959261 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL30143506 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL22700667 | 0.83 | MCL1 (0.69) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14995993 | 0.83 | BCL2L1 (0.71) | BCL2L1MCL1BCL2BCL2L2BCL2A1 | |
| SCHEMBL17372966 | 0.82 | MCL1 (0.82) | BCL2L1MCL1BCL2BCL2L2ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| WO-2025132801-A1 | DISCERNIBLE PROTEIN VARIANTS OF BCL-2 FOR USE IN CELL THERAPY | CIMEIO THERAPEUTICS AG (CH) | 2025-06-26 | — | — | WO | claimed |
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | claimed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | claimed |
| WO-2024263573-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240374610-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | claimed |
| US-12138261-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-12 | — | — | US | claimed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | claimed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | claimed |
| EP-3571196-B1 | NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE | UNIV TEMPLE (US) | 2023-01-04 | — | — | EP | claimed |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | claimed |
| CN-115536496-A | Synthesis method of selective dehydroxy apogossypol | 江苏度未生物工程科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-11524009-B2 | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-12-13 | — | — | US | claimed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | claimed |
| US-20220235042-A1 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER | 2022-07-28 | — | — | US | claimed |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2022-05-12 | — | — | US | claimed |
| CN-112679319-B | Method for synthesizing 1,1' -deoxidized gossypol | 江苏度未生物工程科技有限公司 | 2022-05-03 | — | — | CN | claimed |
| US-11229641-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235042-A1 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, IRAK2 | BCL2L1 63/4885MCL1 27/4885BCL2 91/4885 |
| US-11524009-B2 | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | BCLAF1, BCL2L10, BCOR | BCL2L1 9/4885MCL1 10/4885BCL2 11/4885 |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, LTK, BLK | BCL2L1 37/4885MCL1 98/4885BCL2 20/4885 |
| US-11229641-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885MCL1 14/4885BCL2 1/4885 |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | IRAK1, IRAK4, IRAK2 | BCL2L1 63/4885MCL1 27/4885BCL2 91/4885 |
| US-12138261-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885MCL1 14/4885BCL2 1/4885 |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | BCL2L1 5/4885MCL1 14/4885BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.